Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.990
-0.010 (-0.50%)
At close: Oct 24, 2025, 4:00 PM EDT
1.980
-0.010 (-0.50%)
After-hours: Oct 24, 2025, 5:54 PM EDT
Opus Genetics Revenue
Opus Genetics had revenue of $2.88M in the quarter ending June 30, 2025, with 159.17% growth. This brings the company's revenue in the last twelve months to $15.42M, down -6.25% year-over-year. In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%.
Revenue (ttm)
$15.42M
Revenue Growth
-6.25%
P/S Ratio
4.97
Revenue / Employee
$856,722
Employees
18
Market Cap
125.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
| Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
| Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
| Dec 31, 2021 | 589.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IRD News
- 11 days ago - Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference - GlobeNewsWire
- 23 days ago - Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 - GlobeNewsWire
- 25 days ago - Opus Genetics, Inc. - Special Call - Seeking Alpha
- 25 days ago - Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) - GlobeNewsWire
- 6 weeks ago - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewsWire
- 7 weeks ago - Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 7 weeks ago - Opus Genetics Appoints Rob Gagnon as Chief Financial Officer - GlobeNewsWire